Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (811-820 of 962) with videos related to

Pageof 97
Sort By:
Circulation. Cardiovascular Interventions|April 19, 2019
Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary InterventionMichela Faggioni, Usman Baber, Samantha Sartori, et al.
Journal of the American College of Cardiology|March 23, 2019
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES TrialJ Wouter Jukema, Michael Szarek, Laurien E Zijlstra, et al.
Journal of the American College of Cardiology|September 4, 2024
Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary SyndromeDoron Zahger, Gregory G Schwartz, Weiming Du, et al.
Transfusion|November 27, 2025
Transfusion-related adverse events in patients with restrictive or liberal transfusion strategy. An analysis of the MINT trialShahab Ghafghazi, Lynne Uhl, Brandon Herbert, et al.
World Journal of Cardiology|October 2, 2010
Renal impairment and heart failure with preserved ejection fraction early post-myocardial infarctionVinod Jorapur, Gervasio A Lamas, Zygmunt P Sadowski, et al.
The American Journal of Cardiology|August 6, 2017
Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry)Mikkel Schoos, Jaya Chandrasekhar, Usman Baber, et al.
Thrombosis and Haemostasis|December 11, 2019
Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and MethodologyBehnood Bikdeli, Thomas McAndrew, Aaron Crowley, et al.
JAMA|November 7, 2002
Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trialA Michael Lincoff, Robert M Califf, Frans Van de Werf, et al.
JAMA Cardiology|July 21, 2016
Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 TrialMarc P Bonaca, Deepak L Bhatt, Ton Oude Ophuis, et al.
The Canadian Journal of Cardiology|March 7, 2020
Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERSAna Paula de Faria, Rodrigo Modolo, Ply Chichareon, et al.
Pageof 97

Showing results (811-820 of 962) with videos related to

Sort By:
Pageof 97
Circulation. Cardiovascular Interventions|April 19, 2019
Influence of Baseline Anemia on Dual Antiplatelet Therapy Cessation and Risk of Adverse Events After Percutaneous Coronary InterventionMichela Faggioni, Usman Baber, Samantha Sartori, et al.
Journal of the American College of Cardiology|March 23, 2019
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES TrialJ Wouter Jukema, Michael Szarek, Laurien E Zijlstra, et al.
Journal of the American College of Cardiology|September 4, 2024
Triglyceride Levels, Alirocumab Treatment, and Cardiovascular Outcomes After an Acute Coronary SyndromeDoron Zahger, Gregory G Schwartz, Weiming Du, et al.
Transfusion|November 27, 2025
Transfusion-related adverse events in patients with restrictive or liberal transfusion strategy. An analysis of the MINT trialShahab Ghafghazi, Lynne Uhl, Brandon Herbert, et al.
World Journal of Cardiology|October 2, 2010
Renal impairment and heart failure with preserved ejection fraction early post-myocardial infarctionVinod Jorapur, Gervasio A Lamas, Zygmunt P Sadowski, et al.
The American Journal of Cardiology|August 6, 2017
Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of Non-adherence to Anti-platelet Regimens In Stented Patients Registry)Mikkel Schoos, Jaya Chandrasekhar, Usman Baber, et al.
Thrombosis and Haemostasis|December 11, 2019
Individual Patient Data Pooled Analysis of Randomized Trials of Bivalirudin versus Heparin in Acute Myocardial Infarction: Rationale and MethodologyBehnood Bikdeli, Thomas McAndrew, Aaron Crowley, et al.
JAMA|November 7, 2002
Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trialA Michael Lincoff, Robert M Califf, Frans Van de Werf, et al.
JAMA Cardiology|July 21, 2016
Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 TrialMarc P Bonaca, Deepak L Bhatt, Ton Oude Ophuis, et al.
The Canadian Journal of Cardiology|March 7, 2020
Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERSAna Paula de Faria, Rodrigo Modolo, Ply Chichareon, et al.
Pageof 97